The WOMAN trial evaluated the use of tranexamic acid in postpartum hemorrhage. The key finding of this trial was:
- A Tranexamic acid reduced overall maternal mortality in PPH by 31%
- B Tranexamic acid reduced death due to bleeding by 31% when given within 3 hours of delivery ✓
- C Tranexamic acid increased thromboembolic events and is contraindicated in obstetric hemorrhage
- D Tranexamic acid was beneficial only in cesarean-related hemorrhage
Correct answer: B. Tranexamic acid reduced death due to bleeding by 31% when given within 3 hours of delivery
Explanation
The WOMAN trial (2017) randomized 20,060 women with PPH and found that tranexamic acid reduced death due to bleeding by 31% (RR 0.69) when given within 3 hours of delivery, with no increase in thromboembolic events. Benefit was not seen when administered after 3 hours. The trial did not show reduction in total maternal mortality but specifically demonstrated benefit for hemorrhage-related death. WHO now recommends tranexamic acid (1 g IV) within 3 hours of PPH diagnosis.
Reference: Williams Obstetrics, 26th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.